表皮生长因子抑制剂用于晚期非小细胞肺癌一线治疗患者的分子选择：尚未完全成熟。 - Suppr

Suppr

超能文献

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.

作者信息

Shepherd Frances A

出版信息

J Clin Oncol. 2008 May 20;26(15):2426-7. doi: 10.1200/JCO.2007.15.4286. Epub 2008 May 5.

DOI:10.1200/JCO.2007.15.4286

PMID:18458043

Abstract

摘要

相似文献

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.

J Clin Oncol. 2008 May 20;26(15):2426-7. doi: 10.1200/JCO.2007.15.4286. Epub 2008 May 5.

First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?

Curr Opin Oncol. 2011 Mar;23(2):131-2. doi: 10.1097/CCO.0b013e328341ee26.

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.

Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581.

Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.

Future Oncol. 2017 Feb;13(3):201-204. doi: 10.2217/fon-2016-0325. Epub 2016 Sep 14.

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.

Clin Adv Hematol Oncol. 2015 Mar;13(3):147-9.

Gefitinib. Still no convincing results in non-small cell lung cancer.

Prescrire Int. 2010 Jun;19(107):113.

Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1.

Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.

J BUON. 2016 May-Jun;21(3):754-5.

The cellular origins of drug resistance in cancer.

Nat Med. 2016 Mar;22(3):232-4. doi: 10.1038/nm.4058.

EGFR testing in lung cancer is ready for prime time.

Lancet Oncol. 2009 May;10(5):432-3. doi: 10.1016/S1470-2045(09)70110-X.

引用本文的文献

Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer.

Clin Epigenetics. 2015 Nov 5;7:119. doi: 10.1186/s13148-015-0150-9. eCollection 2015.

Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.

Diagn Pathol. 2015 Jul 12;10:99. doi: 10.1186/s13000-015-0339-4.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361.

[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):529-33. doi: 10.3779/j.issn.1009-3419.2011.06.09.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Nat Rev Clin Oncol. 2009 Jun;6(6):352-66. doi: 10.1038/nrclinonc.2009.62.

Recent advances of novel targeted therapy in non-small cell lung cancer.

J Hematol Oncol. 2009 Jan 21;2:2. doi: 10.1186/1756-8722-2-2.

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.

J Cancer Res Clin Oncol. 2009 Jun;135(6):771-82. doi: 10.1007/s00432-008-0512-1. Epub 2008 Nov 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.

作者信息

Shepherd Frances A

出版信息

J Clin Oncol. 2008 May 20;26(15):2426-7. doi: 10.1200/JCO.2007.15.4286. Epub 2008 May 5.

DOI:10.1200/JCO.2007.15.4286

PMID:18458043

Abstract

摘要

相似文献

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.

J Clin Oncol. 2008 May 20;26(15):2426-7. doi: 10.1200/JCO.2007.15.4286. Epub 2008 May 5.

Curr Opin Oncol. 2011 Mar;23(2):131-2. doi: 10.1097/CCO.0b013e328341ee26.

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.

Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581.

Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.

Future Oncol. 2017 Feb;13(3):201-204. doi: 10.2217/fon-2016-0325. Epub 2016 Sep 14.

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.

Clin Adv Hematol Oncol. 2015 Mar;13(3):147-9.

Gefitinib. Still no convincing results in non-small cell lung cancer.

Prescrire Int. 2010 Jun;19(107):113.

Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1.

Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.

J BUON. 2016 May-Jun;21(3):754-5.

The cellular origins of drug resistance in cancer.

Nat Med. 2016 Mar;22(3):232-4. doi: 10.1038/nm.4058.

EGFR testing in lung cancer is ready for prime time.

Lancet Oncol. 2009 May;10(5):432-3. doi: 10.1016/S1470-2045(09)70110-X.

引用本文的文献

Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer.

Clin Epigenetics. 2015 Nov 5;7:119. doi: 10.1186/s13148-015-0150-9. eCollection 2015.

Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.

Diagn Pathol. 2015 Jul 12;10:99. doi: 10.1186/s13000-015-0339-4.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361.

[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):529-33. doi: 10.3779/j.issn.1009-3419.2011.06.09.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Nat Rev Clin Oncol. 2009 Jun;6(6):352-66. doi: 10.1038/nrclinonc.2009.62.

Recent advances of novel targeted therapy in non-small cell lung cancer.

J Hematol Oncol. 2009 Jan 21;2:2. doi: 10.1186/1756-8722-2-2.

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.

J Cancer Res Clin Oncol. 2009 Jun;135(6):771-82. doi: 10.1007/s00432-008-0512-1. Epub 2008 Nov 20.